Pavankumar Anne, Sankalp Sethi and Matt Furlow co-authored this post with David Kriesman.
In oncology, we’re accustomed to “firsts” in the headlines—new discoveries, novel treatments and scientific breakthroughs offering hope to patients. Most newsworthy updates relate to emerging therapies, but on March 6, we saw a first in oncology diagnostic testing that has started making waves.
In an Aug. 9 op-ed in The New York Times titled “Cancer-Drug Ads vs. Cancer-Drug Reality,” the author contrasted the possible outcomes that pharmaceutical ads convey with the reality of the outcomes that most patients experience. The author has experienced loss in his own family due to cancer, and in the op-ed, he questioned whether ads for the immunotherapy that didn’t work for his loved one are unnecessarily instilling false hope in other patients. As a market researcher and reader of clinical data on drugs, I can see all sides of the story.